BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
11,78 $
arrow_downward
-1,54%(-0,18) 1D
13 հոկ, 11:42:04 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BVNRY...
Open
11,77 $
High
11,78 $
Low
11,77 $
Mkt. cap
2,82 մլրդ
Avg. vol.
3,04 հզր
Volume
830,00
P/E ratio
12,70
52-wk high
13,00 $
52-wk low
8,67 $
EPS
0,93 $
Beta
1,45
Shares outstanding
237,82 մլն
No. of employees
2 հզր
Open
11,77 $
High
11,78 $
Low
11,77 $
Mkt. cap
2,82 մլրդ
Avg. vol.
3,04 հզր
Volume
830,00
P/E ratio
12,70
52-wk high
13,00 $
52-wk low
8,67 $
EPS
0,93 $
Beta
1,45
Shares outstanding
237,82 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
GlobeNewswire
·
1 օր առաջ
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR
CEOPaul Chaplin
Employees1,91 հզր
Founded01 հլս, 1992 թ.
Headquarters-
Sector-
Websitebavarian-nordic.com